Penicillin‑binding protein 1A mutation‑positive Helicobacter pylori promotes epithelial‑mesenchymal transition in gastric cancer via the suppression of microRNA‑134.
Aged
Antigens, Bacterial
/ genetics
Bacterial Proteins
/ genetics
Cell Line, Tumor
Cell Proliferation
Down-Regulation
Epithelial-Mesenchymal Transition
Female
Forkhead Box Protein M1
/ genetics
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Helicobacter Infections
/ complications
Helicobacter pylori
/ genetics
Host-Pathogen Interactions
Humans
Lymphatic Metastasis
Male
MicroRNAs
/ genetics
Middle Aged
Mutation
Penicillin-Binding Proteins
/ genetics
RNA, Small Interfering
Stomach Neoplasms
/ etiology
gastric cancer
Helicobacter pylori
penicillin-binding protein 1A
microRNAs
epithelial-mesenchymal transition
Journal
International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
11
06
2018
accepted:
24
08
2018
pubmed:
21
12
2018
medline:
21
5
2019
entrez:
21
12
2018
Statut:
ppublish
Résumé
Evidence suggests that Helicobacter pylori (H. pylori) is not only the main cause of gastric cancer (GC), but is also closely associated with its metastasis. One of the major virulence factors in H. pylori is the cytotoxin‑associated gene A (CagA). With the growing proportion of amoxicillin‑resistant H. pylori strains, the present study aimed to explore the effects of CagA‑ and penicillin‑binding protein 1A (PBP1A) mutation‑positive H. pylori (H. pyloriCagA+/P+) on GC cells, and its clinical significance. The clinical significance of H. pyloriCagA+/P+ infection was analyzed in patients with GC. In vitro, GC cells were infected with H. pyloriCagA+/P+ to investigate whether it was involved in the epithelial‑mesenchymal transition (EMT) of SGC‑7901 cells using immunofluorescence and western blot analysis. The results of clinical analysis demonstrated that, although CagA‑negative H. pylori infection had no significant association with the characteristics of patients with GC, H. pyloriCagA+/P+ infection was significantly associated with various clinicopathological parameters, including invasion depth, lymphatic metastasis and distant metastasis. In vitro, the results indicated that H. pyloriCagA+/P+ promoted proliferation, invasion and EMT of SGC‑7901 cells. MicroRNA (miR)‑134 was downregulated in H. pyloriCagA+/P+ infected tissues compared with in those with H. pyloriCagA+/P‑ infection. miR‑134 overexpression significantly reversed H. pyloriCagA+/P+ infection‑associated cell proliferation, invasion and EMT. Furthermore, the results revealed that Forkhead box protein M1 (FoxM1) was a direct target of miR‑134, and FoxM1 knockdown impeded H. pyloriCagA+/P+‑induced EMT. In conclusion, the present study demonstrated that miR‑134 may suppress the proliferation, invasion and EMT of SGC‑7901 cells by targeting FoxM1, and may serve a protective role in the process of H. pyloriCagA+/P+‑induced GC. These findings may lead to an improved understanding of H. pyloriCagA+/P+‑associated poor clinical characteristics in patients with GC.
Identifiants
pubmed: 30569124
doi: 10.3892/ijo.2018.4665
pmc: PMC6365042
doi:
Substances chimiques
Antigens, Bacterial
0
Bacterial Proteins
0
FOXM1 protein, human
0
Forkhead Box Protein M1
0
MIRN134 microRNA, human
0
MicroRNAs
0
Penicillin-Binding Proteins
0
RNA, Small Interfering
0
cagA protein, Helicobacter pylori
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
916-928Références
Antimicrob Agents Chemother. 2000 Dec;44(12):3368-73
pubmed: 11083642
Antimicrob Agents Chemother. 2001 Mar;45(3):962-5
pubmed: 11181392
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Antimicrob Agents Chemother. 2002 May;46(5):1273-80
pubmed: 11959556
Antimicrob Agents Chemother. 2002 Jul;46(7):2229-33
pubmed: 12069978
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Cancer Res. 2009 Apr 15;69(8):3501-9
pubmed: 19351851
Lancet Oncol. 2010 Feb;11(2):136-46
pubmed: 20022810
Nat Rev Cancer. 2010 Jun;10(6):403-14
pubmed: 20495574
Lancet. 2011 Aug 6;378(9790):507-14
pubmed: 21777974
Gut. 2012 May;61(5):646-64
pubmed: 22491499
FEBS Lett. 2012 Oct 19;586(20):3761-5
pubmed: 23010597
JAMA. 2013 Feb 13;309(6):578-86
pubmed: 23403682
Mol Cancer Res. 2013 Aug;11(8):834-44
pubmed: 23576572
BMC Microbiol. 2013 May 09;13:103
pubmed: 23659287
PLoS One. 2013 May 07;8(5):e62440
pubmed: 23667477
Int J Cancer. 2014 Feb 15;134(4):811-21
pubmed: 23824713
Int J Med Microbiol. 2013 Dec;303(8):548-52
pubmed: 23972614
Curr Oncol. 2013 Oct;20(5):e388-95
pubmed: 24155636
PLoS One. 2014 Feb 03;9(2):e87665
pubmed: 24498348
World J Gastroenterol. 2014 Feb 14;20(6):1424-37
pubmed: 24587619
Microb Drug Resist. 2014 Dec;20(6):509-16
pubmed: 24901497
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Carcinogenesis. 2014 Nov;35(11):2619-29
pubmed: 25239641
Neoplasma. 2015;62(1):1-15
pubmed: 25563362
DNA Cell Biol. 2015 Jun;34(6):429-36
pubmed: 25811077
Cell Commun Signal. 2015 Jul 11;13:30
pubmed: 26160167
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
Oncol Lett. 2016 Oct;12(4):2445-2450
pubmed: 27698811
Oncol Rep. 2017 Feb;37(2):823-830
pubmed: 28075475
PLoS One. 2017 Feb 2;12(2):e0170942
pubmed: 28152027
Mol Ther Nucleic Acids. 2017 Mar 17;6:140-149
pubmed: 28325280
Cell Microbiol. 2017 Dec;19(12):
pubmed: 28776327
Helicobacter. 2017 Dec;22(6):null
pubmed: 28840971
Oncotarget. 2017 Jul 15;8(40):68180-68190
pubmed: 28978107
Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):342-344
pubmed: 29263184
Oncol Lett. 2017 Dec;14(6):7288-7296
pubmed: 29344165
Front Cell Infect Microbiol. 2018 Jan 15;7:541
pubmed: 29379775
J Environ Pathol Toxicol Oncol. 2017;36(4):309-320
pubmed: 29431063
J Med Microbiol. 2018 Mar;67(3):314-324
pubmed: 29458667
Am J Cancer Res. 2018 Feb 01;8(2):207-225
pubmed: 29511593
Oncol Lett. 2018 Apr;15(4):4592-4598
pubmed: 29541230
N Engl J Med. 2018 Mar 22;378(12):1085-1095
pubmed: 29562147
Brief Bioinform. 2018 Mar 20;:null
pubmed: 29579224
Exp Cell Res. 2018 Jun 15;367(2):196-204
pubmed: 29604247
Toxins (Basel). 2018 Apr 19;10(4):
pubmed: 29671784
Front Microbiol. 2018 Apr 05;9:636
pubmed: 29675003
Nucleic Acids Res. 1997 May 1;25(9):1715-9
pubmed: 9108152
J Clin Microbiol. 1998 Oct;36(10):3048-50
pubmed: 9738066